stockrow
Friday 6 November 2026
Export CAPS’s income statement to Excel — free account
Capstone Therapeutics Corp.
CAPS Basic Materials Building Materials
Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024.
- Revenue
- +67.1%
- EPS
- +15.4%
- Free cash flow
- +73.4%
- Total debt
- +45.9%
Quarter to June 2026, against a year earlier
1.87
0.03
−1.58%
Follow CAPS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.05 | 0.12 | 0.08 | 0.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.23) | (2.23) | (9.21) | 0.00 | |
P/B ratio |
0.26 | 0.56 | 0.31 | 0.30 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.47 | 0.61 | 0.57 | 0.58 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.90) | (6.42) | (6.01) | (21.43) | |
EV/FCF |
(7.46) | (6.25) | (5.85) | (21.07) | |
Quick Ratio |
0.35 | 0.27 | 0.24 | 0.32 | |
Current Ratio |
0.99 | 0.95 | 1.00 | 0.95 | |
Net Debt/EBITDA |
12.95 | (26.46) | (3.45) | (46.35) | |
Debt/Assets |
46.56% | 48.09% | 45.47% | 32.87% | |
Debt/Equity |
2.05 | 2.31 | 1.88 | 0.71 | |
Asset Turnover |
1.13 | 0.97 | 0.95 | 1.51 | |
Operating CF/Net income |
0.28 | 1.46 | 0.03 | 0.00 | |
Capex/Depreciation |
(0.04) | (0.05) | (0.07) | (0.04) | |
Interest Coverage |
0.22 | (1.68) | (3.34) | (1.29) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
25.65% | 35.35% | 38.96% | 24.68% | |
Intangible Assets out of Total Assets |
0.37 | 0.38 | 0.40 | 0.45 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(4.80) | (2.67) | (4.11) | (1.64) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1,320.22%) | (505.75%) | (499.13%) | (607.35%) | |
Free Cash Flow Yield |
(118.83%) | (81.48%) | (117.16%) | (16.52%) | |
Revenue per Share |
51.02 | 40.67 | 70.41 | 71.94 | |
Operating CF per Share |
(0.93) | (8.98) | (2.37) | 0.00 | |
Capex per Share |
(0.15) | (0.09) | (0.80) | (0.08) | |
Free Cash Flow per Share |
(1.08) | (9.07) | (3.17) | (0.08) | |
Cash per Share |
0.53 | 1.35 | 4.10 | 3.85 | |
Shareholders Equity per Share |
29.50 | 36.12 | 70.28 | 143.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.50 | 36.12 | 70.28 | 143.08 | |
Free Cash Flow |
(0.45) | (2.82) | (0.56) | (0.02) | |
Working Capital |
(0.24) | (1.44) | 0.08 | (0.91) | |
Capital Expenditures |
(0.06) | (0.03) | (0.14) | (0.02) | |
Net Current Asset Value |
(15.39) | (16.59) | (15.92) | (12.21) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.43 | 5.71 | 3.81 | — | |
Average Payables |
5.20 | 5.67 | 4.13 | 3.14 | |
Average Inventory |
12.99 | 13.92 | 13.35 | — | |
Average Assets |
53.28 | 53.00 | 49.30 | 29.59 | |
Average Common Equity |
19.32 | 19.08 | 4.68 | 11.22 |
Columns are period end dates · fundamentals updated 2 Nov 2026